Jeil Pharmaceutical Reorganizes Central Research Institute... Appoints Key Figure Behind 'Enblo' Development
Research structure reorganized from three departments into two centers
Park Junseok appointed head of the Central Research Institute
Seong Gisa named head of the Innovative New Drug Center; Kim Hyejeong joins as head of the Innovative New Drug Team
Jeil Pharmaceutical has reorganized its Central Research Institute and brought in outside experts to strengthen its drug research and development capabilities.
Jeil Pharmaceutical said on November 2 that it had reorganized its Central Research Institute on November 1 and appointed Executive Vice President Park Junseok, who joined the company in June, as head of the institute. It also appointed Managing Director Seong Gisa as head of the Innovative New Drug Center and Director Kim Hyejeong as head of the Innovative New Drug Team.
From left: Park Junseok, newly appointed head of Jeil Pharmaceutical's Central Research Institute; Seong Gisa, head of the Innovative Drug Center; and Kim Hyejeong, head of the Innovative Drug Team. Jeil Pharmaceutical
View original imageAs part of the reorganization, Jeil Pharmaceutical shifted its existing function-based research structure to a project-centered one and reassigned research staff. The company plans to strengthen its ability to discover drug candidates by combining its capabilities in developing synthetic drugs with biology and artificial intelligence (AI)-based research.
The previous structure of three departments—the Drug Research Laboratory, the Pharmacology and Toxicology Laboratory, and the Synthetic Research Laboratory—has been replaced by two centers: the Innovative New Drug Center and the Synthetic Research Center. The Innovative New Drug Center will oversee the discovery of drug candidates by integrating medicinal chemistry with cell- and animal-based pharmacology research. The Synthetic Research Center will add early-stage formulation research to its synthetic chemistry and process research, strengthening its chemistry, manufacturing, and controls (CMC) capabilities. A preclinical research team integrating toxicology research has been placed under the direct supervision of the head of the institute. The Research Support Team has been reorganized as the Research Management Team, and its quality assurance (QA) function has been strengthened to improve research management for technology exports and regulatory engagement.
Newly appointed Central Research Institute head Park Junseok is a drug development expert who led the development of Fexuclue, Korea's 34th domestically developed new drug, and Enblo, its 36th. He previously headed the Drug Discovery Center at Daewoong Pharmaceutical and served as chief strategy officer (CSO) at I& Therapeutics. Over the past 30 years, he has led research and development across the process, from drug candidate discovery through regulatory approval, and has also participated in global technology exports.
The Innovative New Drug Center will be led by Center Head Seong Gisa, who has more than 20 years of experience researching cancer biology. Seong worked on drug development at Arvinas, a U.S. company developing targeted protein degradation (TPD) drugs, and has experience leading the discovery of molecular glue degrader (MGD) candidates against novel targets at a Korean biotech company. The Synthetic Research Center will be headed by Managing Director Jeon Seonghyeon, who previously led the Synthetic Research Laboratory. He has spent 30 years working on synthetic drug research and drug process development.
Kim Hyejeong, who has joined as head of the Innovative New Drug Team, is an expert in AI-based drug development and molecular design. She previously led the Platform Technology Team at C&C Research Laboratories and headed the Innovative New Drug Center at HK inno.N. While at C&C Research Laboratories, she secured a technology export deal with global pharmaceutical company Leo Pharma for a drug candidate with a novel mechanism of action to treat atopic dermatitis.
Building on its organizational restructuring and recruitment of specialists, Jeil Pharmaceutical plans to strengthen the development competitiveness of its in-house drug pipeline and expand next-generation drug research, focusing on cancer and complex age-related diseases. Its solid-tumor cancer drug candidate JP9441 is currently undergoing preclinical studies ahead of entry into Phase 1 clinical trials. JP10259, a treatment candidate for idiopathic pulmonary fibrosis (IPF), has completed candidate selection and entered preclinical studies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
"This reorganization is intended to advance our existing strength in synthetic drug development while building up our capabilities in biological mechanism research, and to create an environment where researchers can focus more deeply on their projects," said Park Junseok, head of Jeil Pharmaceutical's Central Research Institute. "Through our new research organization, we will pursue the development of the world's first innovative drugs and generate global technology export results."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.